The Food and Drug Administration June 20 released guidance on a new voluntary pilot program intended to improve certain laboratory-developed tests used to identify patients for treatment with certain oncology drug products. The program will ask drug makers to provide performance information for the tests used to enroll patients in clinical trials for their drug, which FDA will use to post recommended minimum performance characteristics for similar tests to select patients for treatment with the approved drug. 
 
“We believe this guidance and the launch of the pilot program are important steps towards addressing safety risks posed by the use of poorly performing laboratory developed tests,” said Jeff Shuren, M.D., director of the FDA’s Center for Devices and Radiological Health. “The pilot aims to help by making transparent performance recommendations for diagnostic tests used to select certain oncology drug treatments.”

Related News Articles

Chairperson's File
Teams at hospitals and health systems understand that social needs and economic circumstances have a significant impact on an individual’s health and well-…
Headline
In this podcast, three leaders from rural health care systems agree that every community must find its own unique way to maximize new partnerships and…
Chairperson's File
For the past 125 years, the AHA has been a tireless advocate for the health care field, patients and communities. We need this diligent work and bold…
#HealthCareInnovation Blog
In the midst of managing the impact of the COVID-19 pandemic, health care teams also have been dealing with natural disasters — including wildfires,…
Chairperson's File
Hospital and health system teams today not only are caring for one patient at a time but also improving the health of their communities. Take, for example, a…
#HealthCareInnovation Blog
Teamwork and communication are fairly simple concepts that we know are important in health care. Research shows they are the right thing to do — for…